Avance Biosciences now offers LC-MS/MS services to support precise bioanalytical testing for small molecules, peptides, oligonucleotides, and biomarkers, enhancing drug development with advanced PK/PD, impurity profiling, and targeted proteomics capabilities...
Avance Biosciences has launched a state-of-the-art NGS Center of Excellence in Houston to support biologics and cell and gene therapy development. The facility offers advanced sequencing technologies, GMP- and CLIA-compliant testing, and expert bioinformatics, providing comprehensive support from early research through clinical trials and regulatory submissions...
Avance Biosciences™ is proud to announce its participation in the Bioprocessing Summit 2025 in Boston, MA. Visit Booth #516 to learn how our GLP- and GMP-compliant analytical services support the development and manufacturing of biologics, cell and gene therapies, and advanced biotherapeutics...
Our existing 28,000 sq. ft. of lab space is expanding by an additional 17,000 sq. ft., enhancing our GLP, GMP and CLIA testing capabilities...
Avance delivers end-to-end NGS workflow compliance with a robust framework for data integrity, pipeline validation, and audit readiness—tailored for regulated environments...
An NIH-supported team has delivered the first personalized CRISPR-based gene therapy to an infant with CPS1 deficiency, offering new hope for rare disease treatment. The customized approach shows early success and may pave the way for future individualized therapies...
The FDA is embracing AI to streamline drug reviews, aiming for full implementation by June 2025. Following a successful pilot, this move could fast-track therapy approvals and reduce administrative tasks for scientists...
Verve Therapeutics’ VERVE-102 shows early success in lowering LDL cholesterol by 55% with a single dose, offering a potential one-time gene editing treatment for familial hypercholesterolemia...
MIT engineers have developed a gene circuit that precisely controls gene expression, offering potential breakthroughs in gene therapy for disorders like fragile X syndrome. This advancement helps ensure therapeutic genes are expressed at optimal levels, minimizing risks and paving the way for more effective treatments...
Avance Biosciences is excited to exhibit at the ASGCT 2025 conference in New Orleans, LA, from May 13–17, 2025. Join us to explore our expert bioanalytical solutions for gene and cell therapy development. Visit booth #750 to learn how we can support your therapeutic advancements...
